The director of headache services at NYU Langone discussed the 2019 American College of Emergency Physicians guidelines on acute nontraumatic headache in the emergency department.
The drug, which is a schedule IV controlled substance, is the first nasal spray approved as rescue medication in patients 6 years and older with epilepsy.
The professor of neurology at NYU Langone Medical Center discussed the importance of these safety data for intranasal diazepam, and why future comparative data would be essential.
The proprietary formulation of aspirin and fumaric acid addresses issues with pretreating fumarate flush, a bothersome side effect of popular MS disease-modifying therapy Tecfidera.
The professor of neurology at NYU Langone offered insight into the state of affairs with current seizure rescue medications and added her insight into how intranasal diazepam may improve the patient experience.
The professor of neurology at NYU Langone spoke to her clinical experience with cenobamate and how she anticipates it might be utilized once it becomes commercially available.
The professor of neurology at NYU Langone discussed cenobamate’s potential as a treatment option for patients who have uncontrolled seizures, as well as its ability to bring a high number of patients toward complete seizure freedom.
In an interview with NeurologyLive, Andrew S. Feigin, MD, details ongoing trials that aim to treat Huntington disease, including the notable SIGNAL trial.